The full results of the phase III REVERSE-IT trial continue to show that ticagrelor (Brilinta)-reversing therapy bentracimab ...

The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three ...

A “Strong Buy” rating from Wall Street indicates that analysts believe a stock has the potential for future price ...

which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric ...

In addition, their solubility is strongly affected by the pH of the solution.However, the solubility of phosphate in waters containing hydrated iron(III) oxides is reduced by orders of magnitude, ...

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron ...

A new study lacked significant results, but when combined with additional studies, the prevention of cardiovascular events ...

In patients with heart failure and iron deficiency, ferric carboxymaltose did not significantly reduce the time to first heart failure hospitalization or cardiovascular death in the overall cohort or ...

Ancient oceans, which were heavy on iron, interacted differently with light wavelengths, retracting green light into the ...

But on Thursday, March 27, the U.S. Consumer Product Safety Commission (CPSC) announced a nationwide recall on “about 17,660” ...

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...